|
1AS4
CLEAVED ANTICHYMOTRYPSIN A349R
Deposited 1997-08-12
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
43–383(341 aa)
Fragment:CHAIN A CONTAINS RESIDUES 20 - 358, CHAIN B CONTAINS RESIDUES 359 - 393
Chain B
387–423(37 aa)
Fragment:CHAIN A CONTAINS RESIDUES 20 - 358, CHAIN B CONTAINS RESIDUES 359 - 393
|
Mutation:A349R
Mutation:A349R
|
ACT ACETATE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6;14% PEG MONOMETHYLETHER 5000, 0.2 M MAGNESIUM ACETATE 0.1 M SODIUM ACETATE PH 5.6 PROTEIN AT 3 MG/ML
|
Resolution 2.10 Å
R-free 0.240
|
|
1QMN
Alpha1-antichymotrypsin serpin in the delta conformation (partial loop insertion)
Deposited 1999-10-04
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
26–423(398 aa)
|
Mutation:YES
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 4.5;291 K;1 MICROLITER OF 10MG/ML PROTEIN IN 50MM TRIS, 50MM KCL, PH 7.4 WAS MIXED WITH 2 MICROLITER OF PRECIPITANT AND EQUILIBRATED AS A HANGING DROP OVER 1ML OF PRECIPITANT (20% [W/V] PEG 4000, 0.2M AMMONIUM SULPHATE, 0.1M NAOAC, PH 4.5), AT 18 DEGREES C
|
Resolution 2.27 Å
R-free 0.243
|
|
2ACH
CRYSTAL STRUCTURE OF CLEAVED HUMAN ALPHA1-ANTICHYMOTRYPSIN AT 2.7 ANGSTROMS RESOLUTION AND ITS COMPARISON WITH OTHER SERPINS
Deposited 1993-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Other combination
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
24–383(360 aa)
Chain B
384–423(40 aa)
|
Not recorded
|
PO4 PHOSPHATE ION × 1
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.70 Å
|
|
2ACH
CRYSTAL STRUCTURE OF CLEAVED HUMAN ALPHA1-ANTICHYMOTRYPSIN AT 2.7 ANGSTROMS RESOLUTION AND ITS COMPARISON WITH OTHER SERPINS
Deposited 1993-04-26
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Other combination
Homooligomer;Protein × 4
PDB declaration: tetrameric
|
Chain A
24–383(360 aa)
Chain B
384–423(40 aa)
|
Not recorded
|
PO4 PHOSPHATE ION × 2
|
X-RAY DIFFRACTION
mmCIF provides none of the parsed conditions
|
Resolution 2.70 Å
|
|
3CAA
CLEAVED ANTICHYMOTRYPSIN A347R
Deposited 1997-08-18
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
43–383(341 aa)
Chain B
387–423(37 aa)
|
Mutation:A347R
Mutation:A347R
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6;10% PEG MONOMETHYLETHER 5000 0.2 M MAGNESIUM ACETATE 0.1 M SODIUM CITRATE PH 5.6 PROTEIN AT 3 MG/ML
|
Resolution 2.40 Å
R-free 0.280
|
|
3DLW
Antichymotrypsin
Deposited 2008-06-29
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
25–423(399 aa)
|
Mutation:A351G, A352T, V370T
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;pH 7.5;294 K;PEG 10,000, HEPES buffer, pH 7.5, VAPOR DIFFUSION, HANGING DROP, temperature 294K
|
Resolution 2.70 Å
R-free 0.286
|
|
4CAA
CLEAVED ANTICHYMOTRYPSIN T345R
Deposited 1997-08-14
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
43–383(341 aa)
Chain B
387–423(37 aa)
|
Mutation:T345R
Mutation:T345R
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
pH 5.6;14% PEG 8000 0.2 M MAGNESIUM ACETATE 0.1 M SODIUM CITRATE PH 5.6
|
Resolution 2.90 Å
R-free 0.284
|
|
5OM2
Crystal structure of Alpha1-antichymotrypsin variant DBS-I1: a drug-binding serpin for doxycycline
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274A W276F R277F V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383H D384F Q386W N387S
;
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274A W276F R277F V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383H D384F Q386W N387S
;
|
EDO 1,2-ETHANEDIOL × 1
DXT (4S,4AR,5S,5AR,6R,12AS)-4-(DIMETHYLAMINO)-3,5,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M ammonium chloride,
20 % w/v PEG 3350
|
Resolution 1.47 Å
R-free 0.202
|
|
5OM3
Crystal structure of Alpha1-antichymotrypsin variant DBS-I5: a MMP14-cleavable drug-binding serpin for doxycycline
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F V355L K356F T358P L360S S361L A362R L363M P382D T383H D384F Q386W N387S
Mutation:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F V355L K356F T358P L360S S361L A362R L363M P382D T383H D384F Q386W N387S
|
PEG DI(HYDROXYETHYL)ETHER × 1
DXT (4S,4AR,5S,5AR,6R,12AS)-4-(DIMETHYLAMINO)-3,5,10,12,12A-PENTAHYDROXY-6-METHYL-1,11-DIOXO-1,4,4A,5,5A,6,11,12A-OCTAHYDROTETRACENE-2-CARBOXAMIDE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M ammonium sulfate, 0.1 M BIS-TRIS pH 5.5, 25 % w/v PEG 3350
|
Resolution 2.00 Å
R-free 0.219
|
|
5OM5
Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo1: an allosterically triggered drug-binding serpin for doxycycline
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F A349R V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383H D384F Q386W N387S
;
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F A349R V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383H D384F Q386W N387S
;
|
EDO 1,2-ETHANEDIOL × 3
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.1 M HEPES pH 7.0, 30 % v/v
Jeffamine ED-2001 pH 7.0
|
Resolution 1.59 Å
R-free 0.196
|
|
5OM6
Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo2: a MMP9-cleavable drug-binding serpin for doxycycline
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Fragment:UNP residues 36-383
Chain B
384–423(40 aa)
Fragment:UNP residues 384-423
|
Mutation:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F A349R V355L I357G T358P L359R L360Q
Mutation:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F A349R V355L I357G T358P L359R L360Q
|
CIT CITRIC ACID × 1
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.1 M citric acid pH 3.5, 25 % w/v PEG 3350
|
Resolution 1.85 Å
R-free 0.238
|
|
5OM6
Crystal structure of Alpha1-antichymotrypsin variant DBS-I-allo2: a MMP9-cleavable drug-binding serpin for doxycycline
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain C
26–383(358 aa)
Fragment:UNP residues 36-383
Chain D
384–423(40 aa)
Fragment:UNP residues 384-423
|
Mutation:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F A349R V355L I357G T358P L359R L360Q
Mutation:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F A349R V355L I357G T358P L359R L360Q
|
CIT CITRIC ACID × 1
EDO 1,2-ETHANEDIOL × 1
CL CHLORIDE ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.1 M citric acid pH 3.5, 25 % w/v PEG 3350
|
Resolution 1.85 Å
R-free 0.238
|
|
5OM7
Crystal structure of Alpha1-antichymotrypsin variant DBS-II: a drug-binding serpin for doxorubicin
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F D278E V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383N D384F Q386W N387S
;
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F D278E V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383N D384F Q386W N387S
;
|
DM2 DOXORUBICIN × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M ammonium chloride, 20 % w/v
PEG 3350
|
Resolution 1.73 Å
R-free 0.235
|
|
5OM8
Crystal form 2 of Alpha1-antichymotrypsin variant DBS-II-allo: an allosterically modulated drug-binding serpin for doxorubicin
Deposited 2017-07-28
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F D278E A349R V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383N D384F Q386W N387S
;
Mutation:;L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F D278E A349R V355L K356E I357V T358L L359F L360Q S361G A362P P382D T383N D384F Q386W N387S
;
|
CL CHLORIDE ION × 1
EDO 1,2-ETHANEDIOL × 1
NI NICKEL (II) ION × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M Ammonium chloride, 20% w/v
PEG 3350
|
Resolution 2.20 Å
R-free 0.242
|
|
6FTP
Crystal form 1 of Alpha1-antichymotrypsin variant DBS-II-allo: an allosterically modulated drug-binding serpin for doxorubicin
Deposited 2018-02-22
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
386–423(38 aa)
|
Mutation:L24R W194F W215Y E242Q K244N L269S P270Q K274S W276F R277F D278E A349R V355L K356E I357V T358L L359F L360Q
Mutation:S361G A362P P382D T383N D384F Q386W N387S
|
EDO 1,2-ETHANEDIOL × 3
DM2 DOXORUBICIN × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M sodium thiocyanate, 20 % w/v PEG 3350
|
Resolution 1.80 Å
R-free 0.221
|
|
6HGD
Crystal structure of Alpha1-antichymotrypsin variant NewBG-0: a new binding globulin variant that is devoid of any cortisol-binding capabilities
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, E242Q, K244N, K274N, R277G
Mutation:P382D, T383H, D384F, Q386W
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M magnesium chloride hexahydrate, 0.1 M BIS-Tris pH 6.5, 25 % w/v PEG 3350
|
Resolution 1.90 Å
R-free 0.198
|
|
6HGE
Crystal structure of Alpha1-antichymotrypsin variant NewBG-I in the uncleaved S-conformation
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain A
26–423(398 aa)
|
Mutation:L24R, E242Q, K244N, L269S, P270R, K274N, R277G, P382D, T383H, D384F, Q386W, N387S
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M NaCl, 0.1 M Tris-HCl, pH 8.5, 25 % PEG 3350 supplemented with 10 % of a 0.5 M NaF solution, and additional 0.1 ul of a silver bullets bio reagent mixture consisting of thymidine, adenosine 3,5-cyclic monophosphate sodium salt monohydrate, sarcosine, 4-aminobenzoic acid, acarbose, inosine, 0.02 M HEPES sodium pH 6.8
|
Resolution 2.80 Å
R-free 0.262
|
|
6HGE
Crystal structure of Alpha1-antichymotrypsin variant NewBG-I in the uncleaved S-conformation
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 2
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain B
26–423(398 aa)
|
Mutation:L24R, E242Q, K244N, L269S, P270R, K274N, R277G, P382D, T383H, D384F, Q386W, N387S
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M NaCl, 0.1 M Tris-HCl, pH 8.5, 25 % PEG 3350 supplemented with 10 % of a 0.5 M NaF solution, and additional 0.1 ul of a silver bullets bio reagent mixture consisting of thymidine, adenosine 3,5-cyclic monophosphate sodium salt monohydrate, sarcosine, 4-aminobenzoic acid, acarbose, inosine, 0.02 M HEPES sodium pH 6.8
|
Resolution 2.80 Å
R-free 0.262
|
|
6HGE
Crystal structure of Alpha1-antichymotrypsin variant NewBG-I in the uncleaved S-conformation
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 3
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain C
26–423(398 aa)
|
Mutation:L24R, E242Q, K244N, L269S, P270R, K274N, R277G, P382D, T383H, D384F, Q386W, N387S
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M NaCl, 0.1 M Tris-HCl, pH 8.5, 25 % PEG 3350 supplemented with 10 % of a 0.5 M NaF solution, and additional 0.1 ul of a silver bullets bio reagent mixture consisting of thymidine, adenosine 3,5-cyclic monophosphate sodium salt monohydrate, sarcosine, 4-aminobenzoic acid, acarbose, inosine, 0.02 M HEPES sodium pH 6.8
|
Resolution 2.80 Å
R-free 0.262
|
|
6HGE
Crystal structure of Alpha1-antichymotrypsin variant NewBG-I in the uncleaved S-conformation
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 4
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain D
26–423(398 aa)
|
Mutation:L24R, E242Q, K244N, L269S, P270R, K274N, R277G, P382D, T383H, D384F, Q386W, N387S
Non-standard monomer:Yes (specific site not provided by mmCIF)
|
No recorded non-water small molecule
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;0.2 M NaCl, 0.1 M Tris-HCl, pH 8.5, 25 % PEG 3350 supplemented with 10 % of a 0.5 M NaF solution, and additional 0.1 ul of a silver bullets bio reagent mixture consisting of thymidine, adenosine 3,5-cyclic monophosphate sodium salt monohydrate, sarcosine, 4-aminobenzoic acid, acarbose, inosine, 0.02 M HEPES sodium pH 6.8
|
Resolution 2.80 Å
R-free 0.262
|
|
6HGF
Crystal structure of Alpha1-antichymotrypsin variant NewBG-II: a new binding globulin in complex with cortisol
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, E242Q, K244N, L269S, P270R, K274A, R277G
Mutation:P382D, T383H, D384F, Q386W, N387S
|
EDO 1,2-ETHANEDIOL × 2
HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.2 M ammonium sulfate, 20 % w/v PEG 3350
|
Resolution 1.65 Å
R-free 0.187
|
|
6HGG
Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with cortisol
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, E242Q, K244N, A251V, L252F, L269S, P270R, K274A, R277G
Mutation:P382D, T383H, D384F, Q386W, N387S
|
HCY (11alpha,14beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione × 1
EDO 1,2-ETHANEDIOL × 5
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;2 % v/v Tacsimate pH 5.0, 0.1 M sodium citrate tribasic dihydrate pH 5.6, 16 % w/v PEG 3350
|
Resolution 1.79 Å
R-free 0.216
|
|
6HGH
Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin without any bound ligand
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, E242Q, K244N, A251V, L252F, L269S, P270R, K274A, R277G
Mutation:P382D, T383H, D384F, Q386W, N387S
|
MLA MALONIC ACID × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;4 % Tacsimate pH 4.0, 12 % w/v PEG 3350
|
Resolution 1.90 Å
R-free 0.240
|
|
6HGI
Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with corticosterone
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, E242Q, K244N, A251V, L252F, L269S, P270R, K274A, R277G
Mutation:P382D, T383H, D384F, Q386W, N387S
|
C0R CORTICOSTERONE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;2 % v/v Tacsimate pH 5.0, 0.1 M sodium citrate tribasic dihydrate pH 5.6, 16 % w/v PEG 3350
|
Resolution 1.52 Å
R-free 0.193
|
|
6HGJ
Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with aldosterone
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, E242Q, K244N, A251V, L252F, L269S, P270R, K274A, R277G
Mutation:P382D, T383H, D384F, Q386W, N387S
|
AS4 ALDOSTERONE × 1
EDO 1,2-ETHANEDIOL × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;292 K;2 % v/v Tacsimate pH 5.0, 0.1 M sodium citrate tribasic dihydrate pH 5.6, 16 % w/v PEG 3350
|
Resolution 1.82 Å
R-free 0.221
|
|
6HGK
Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with progesterone
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, E242Q, K244N, A251V, L252F, L269S, P270R, K274A, R277G
Mutation:P382D, T383H, D384F, Q386W, N387S
|
STR PROGESTERONE × 1
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;2 % Tacsimate pH 6.0, 0.1 M BIS-Tris pH 6.5, 20 % w/v PEG 3350
|
Resolution 1.85 Å
R-free 0.227
|
|
6HGL
Crystal structure of Alpha1-antichymotrypsin variant NewBG-III: a new binding globulin in complex with testosterone
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, E242Q, K244N, A251V, L252F, L269S, P270R, K274A, R277G
Mutation:P382D, T383H, D384F, Q386W, N387S
|
TES TESTOSTERONE × 1
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;2 % v/v Tacsimate pH 5.0, 0.1 M sodium citrate tribasic dihydrate pH 5.6, 16 % w/v PEG 3350
|
Resolution 1.92 Å
R-free 0.224
|
|
6HGM
Crystal structure of Alpha1-antichymotrypsin variant NewBG-III-allo: an allosterically controlled new binding globulin with an unprecedentedly high ligand release efficacy
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, E242Q, K244N, A251V, L252F, L269S, P270R, K274A, R277G, A349R
Mutation:P382D, T383H, D384F, Q386W, N387S
|
CL CHLORIDE ION × 3
CA CALCIUM ION × 3
EDO 1,2-ETHANEDIOL × 2
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, HANGING DROP;293 K;0.3 M calcium chloride dihydrate, 20 % w/v PEG 3350
|
Resolution 1.37 Å
R-free 0.181
|
|
6HGN
Crystal structure of Alpha1-antichymotrypsin variant DBS-II-allo-L55V: an allosterically controlled doxorubicin-binding serpin with an unprecedentedly high ligand release efficacy
Deposited 2018-08-23
|
Different construct
Different mutation/modification
Different oligomeric state
Different ligand/ion
Different experimental method
Different experimental conditions
Different structure-quality metrics
|
Assembly 1
Protein homooligomer
Homooligomer;Protein × 2
PDB declaration: dimeric
|
Chain A
26–383(358 aa)
Chain B
384–423(40 aa)
|
Mutation:L24R, L55V, W194F,W215Y, E242Q, K244N, L269S, P270Q, K274S, W276F, R277F, D278E, A349R, V355L, K356E, I357V, T358L, L359F, L360Q
Mutation:S361G, A362P, P382D, T383N, D384F, Q386W, N387S
|
EDO 1,2-ETHANEDIOL × 4
|
X-RAY DIFFRACTION
X-ray crystallization conditions
VAPOR DIFFUSION, SITTING DROP;293 K;2 % Tacsimate pH 4.0, 0.1 M Sodium acetate trihydrate pH 4.6, 16 % w/v PEG 3,350
|
Resolution 1.48 Å
R-free 0.199
|
|
9D7K
Infectious B19V capsid
Deposited 2024-08-16
|
Different construct
Different oligomeric state
Different structure-quality metrics
|
Assembly 1
Protein monomer
Monomer;Protein × 1
PDB declaration: monomeric
|
Chain S
1–423(423 aa)
|
Not recorded
|
No recorded non-water small molecule
|
ELECTRON MICROSCOPY
cryo-EM buffer
pH 7
cryo-EM vitrification conditions
Cryogen ETHANE
|
Resolution 3.00 Å
|